




THINGS YOU NEED TO KNOW ABOUT TYPE 2 INFLAMMATORY DISEASES

WHAT IS TYPE 2 INFLAMMATION?

Recent scientific developments have shown that excessive type 2 inflammation, an overactive immune system response, underlies different inflammatory diseases including AD, Asthma, and NP.^{1,2}



WHAT ARE THE SYMPTOMS OF TYPE 2 INFLAMMATION?

Signs and symptoms vary by disease. For instance, type 2 inflammation can contribute to the debilitating itch of atopic dermatitis,⁴ unpredictable and sometimes life-threatening asthma attacks,^{5,6} and the loss of smell and taste associated with chronic rhinosinusitis with nasal polyps.^{7,8}

WHAT FACTORS PLAY A ROLE IN TYPE 2 INFLAMMATION?

Genetic, environmental, and other physiological factors play a role in the presence of type 2 inflammation. The genetics of type 2 inflammation may explain why some people experience more than one of these conditions throughout the course of their life, and why these conditions can run in families.

CAN PEOPLE HAVE MORE THAN ONE TYPE 2 INFLAMMATORY DISEASE?

It is not uncommon for people to have two or more type 2 inflammatory diseases, with different levels of severity. When a person has multiple coexisting type 2 inflammatory diseases, management is even more challenging.



Up to 35% of people with asthma also have AD and up to 50% of those with AD have asthma.^{11,12}



About 17% of people with CRSwNP also have AD and around 13% of those with AD have CRSwNP.^{14,15}



Around 50% of people with CRSwNP also have asthma and up to 45% of those with severe asthma have CRSwNP.^{13,16,17}

WHAT IS THE BURDEN OF DISEASE ASSOCIATED WITH TYPE 2 INFLAMMATORY DISEASES?

Type 2 inflammatory diseases can affect both physical and mental health, with the severity of disease burden increasing when diseases are coexisting. People with inadequately controlled, moderate-to-severe type 2 inflammatory diseases commonly experience frequent and debilitating sleep disturbances and mental health issues.^{1,8,9,10,13-23}



About 46% of adolescents with AD have their school life negatively impacted by AD flares.⁸



Up to 50% of people with severe asthma report symptoms of depression.¹⁴



More than 90% of people with CRSwNP report sleep quality loss.¹⁴

1 - N. A. Gandhi, B. L. Bennett and N. M. Gosham, "Targeting key proximal drivers of type 2 inflammation in disease," *Nature Reviews Drug Discovery*, vol. 15, no. 1, pp. 35-50, 16 October 2016. 2 - S. Carr, E. Chan, and W. Watson, "Eosinophilic esophagitis," *Allergy Asthma & Clinical Immunology*, vol. 14, no. Suppl 1, p. 58, 2018. 3 - J. W. Skov and J. S. Wilson, "Aspirin-exacerbated respiratory disease: pathophysiological insights and clinical advances," *Journal of Allergy and Clinical Immunology*, vol. 9, pp. 37-43, 2016. 4 - T. Zuberbier, S. Olliver and A. Paller, "Patient perspectives on the management of atopic dermatitis," *Journal of Allergy and Clinical Immunology*, vol. 118, no. 1, pp. 225-232, 2006. 5 - Global Initiative for Asthma (GINA), *Global Strategy for Asthma Management and Prevention*, 2019. Available at: <http://asthma.org/download/2019/>. Last accessed April 2018. 6 - P. D. Fletcher, M. van der Molen, T. Asthma control and management in 8,000 European patients: the RESPIRASE Asthma and LRA to Symptoms and Experience (REALISE) Survey. *NPJ Prim Care Respir Med* 2014;24:14203. 7 - Kato A et al. Immunopathology of chronic rhinosinusitis. *Allergy Int*. 2015; Apr; 64(2):121-30. 8 - Neaton JR, Ab-Sae KW. A review of nasal polyps. *The Clin Risk Manag*. 2008;4(2):507-12. 9 - P. Morice, R. Arnold and S. Ekim, "A retrospective, randomized study of asthma control in the UK: results of the CHART study," *Current Medical Research and Opinion*, vol. 24, no. 12, pp. 3443-3452, 2008. 10 - E. Florio, R. Franco and H. Hacemanto, "Lack of control of severe asthma is associated with co-existence of moderate-to-severe rhinitis," *Allergy*, vol. 63, no. 5, pp. 554-559, 2008. 11 - C. Philpott, S. Enkin and C. Hopkins, "Prevalence of asthma, aspirin sensitivity and allergen-chronic rhinosinusitis: data from the UK National Chronic Rhinosinusitis Epidemiology Study," *Respiratory Research*, vol. 10, p. 129, 2018. 12 - H. Won, Y. Kim and M. Kang, "Age-related prevalence of chronic rhinosinusitis and nasal polyps and their relationships with allergic rhinitis," *Ann Allergy Asthma Immunol*, vol. 120, no. 4, pp.

359-364, 2016. 13 - E. Simpson, E. Galbraith-Hayley and D. Margolis, "Chronicity, comorbidity, and life course impairment in atopic dermatitis: insights from a cross-sectional study in US adults," in 25th European Academy of Dermatology and Venereology (EADV) Congress, Vienna, 2016; 14 - L. Rudnik and Z. Soler, "Medical Therapies for Adult Chronic Sinusitis: A Systematic Review," *JAMA Dermatology*, vol. 214, no. 9, pp. 920-929, 2015. 15 - C. Reed, R. Wright and M. Catania, "Mediators of asthma outcomes," *J Allergy Clin Immunol*, vol. 128, no. 301, pp. 136-141, 2012. 16 - D. Stoll, L. Roberts and L. Frank, "Relationship of nasal congestion with sleep, mood, and productivity," *Current Medical Research and Opinion*, vol. 23, no. 4, pp. 811-819, 2007. 17 - S. Norris, E. Bjorngaard and P. Olsson, "Effects of smell loss on daily life and adopted coping strategies in patients with nasal polyps with asthma," *Acta Oto-Laryngologica*, vol. 131, no. 8, pp. 805-810, 2011. 18 - M. Inadomi, C. Pieklo and N. Shew, "Topical calcineurin inhibitors in the treatment of atopic dermatitis: a meta-analysis of current evidence," *Am J Clin Dermatol*, vol. 5, no. 4, pp. 267-278, 2004. 19 - J. Cury Martins, C. Martins and V. Aoki, "Topical tacrolimus for atopic dermatitis (Review)," *The Cochrane Collaboration*. Published by John Wiley & Sons, Ltd. 2016. 20 - S. Muggli, J. Gray and N. Reynolds, "Acetaminophen classed by benzopyrone methylphenylacetate activity for moderate to severe atopic eczema: a double-blind, randomized controlled trial," *Lancet*, vol. 367, no. 9513, pp. 839-846, 2006. 21 - D. Ashcroft, P. Dimmock and R. Garside, "Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomized controlled trials," *BMJ*, vol. 330, no. 7490, pp. 515-522, 2005. 22 - M. Schram, E. Roelcke and M. Leifgaard, "A randomized trial of methotrexate versus azathioprine for severe atopic eczema," *J Allergy Clin Immunol*, vol. 128, no. 2, pp. 353-359, 2011. 23 - Philpott, C. Hopkins and S. Enkin, "The burden of reinvested sinusitis surgery in the UK - data from the Chronic Rhinosinusitis Epidemiology Study (CRSES): a cross-sectional study," *BMJ Open*, vol. 5, p. e006980, 2015.